Dietary Methionine Restriction with FOLFOX Regimen as First Line Therapy of Metastatic Colorectal Cancer: A Feasibility Study
Dietary Methionine Restriction with FOLFOX Regimen as First Line Therapy of Metastatic Colorectal Cancer: A Feasibility Study
复制标题
DOI：
10.1159/000313700
复制
发表时间：
2010-01-01
期刊：
影响因子：
3.5
通讯作者：
Thivat, Emilie
中科院分区：
文献类型：
--
作者：
Durando, Xavier;Farges, Marie-Chantal;Thivat, Emilie
肿瘤细胞对蛋氨酸(MET)的依赖为靶向肿瘤细胞和加强化疗治疗开辟了有趣的前景，如5-氟尿嘧啶(5-FU)和铂化合物。由于MET剥夺可以单独增强5-FU、亚叶酸钙和草酸铂(FOLFOX)48小时联合方案中使用的不同化疗药物，我们启动了一项将饮食MET限制与转移性结直肠癌患者FOLFOX方案相关联的可行性研究。目的：(I)评估血浆MET浓度的耗竭，以及(Ii)评估这种组合的可行性。方法：11例患者入选本研究。他们接受了中位数的3个两周周期的无MET饮食(连续3天)和FOLFOX6方案。结果：限制膳食MET可降低血浆MET浓度，在无MET饮食的第1天，血浆MET浓度下降58%。事实上，我们证明了无MET饮食与FOLFOX方案相关联的可行性和良好的耐受性(营养状况和毒性)。尽管对饮食的依从性很好，但这项研究揭示了在接下来的几个月里实施这种组合的困难。在4名可评价疗效的患者中，3名患者部分缓解，1名患者病情稳定。版权所有(C)2010 S.Karger AG，巴塞尔
The methionine (MET) dependency of tumor cells opens interesting perspectives for targeting tumor cells and potentiating chemotherapy treatment, like 5-fluorouracil (5-FU) and platinum compound. Since MET deprivation can individually potentiate the different chemotherapeutic agents used in the 48-hour combined regimen of 5-FU, leucovorin and oxaliplatin (FOLFOX) regimen, we initiated a feasibility study associating dietary MET restriction with the FOLFOX regimen in patients with metastatic colorectal cancer. Objectives: (i) To evaluate the depletion in the plasma MET concentration, and (ii) to assess the feasibility of this combination. Methods: Eleven patients were enrolled in this study. They received a median number of 3 two-week cycles of a MET-free diet (3 consecutive days) and FOLFOX6 regimen. Results: The plasma MET concentration was reduced by dietary MET restriction, with a depletion of 58% on the 1st day of MET-free diet. Indeed, we demonstrated the feasibility and good tolerance (nutritional status and toxicity) of the association of a MET-free diet with the FOLFOX regimen. Despite good compliance to the diet, this study revealed the difficulty of administering this combination during further months. Among the 4 patients evaluable for response, 3 experienced a partial response and 1 patient a disease stabilization. Copyright (C) 2010 S. Karger AG, Basel